Zimmer Biomet Holdings, Inc.

• ZBH Stock Price 24h change: +0.67%. From 86.02 USD to 86.60 USD. Price action reflects a slight rebound following a dividend payment on January 30th and institutional position adjustments by major funds like New York State Common Retirement Fund.
• Technical Indicators: 50-day MA is $91.01; 200-day MA is $95.97; RSI (14) is ~41.09 (Neutral). The stock is in a long-term bearish trend, currently trading near its 52-week low ($84.59), though it shows short-term consolidation and a potential "setup" opportunity due to reduced volatility.
• Zimmer Biomet paid its quarterly dividend of $0.24 per share on January 30, 2026, maintaining an annualized yield of approximately 1.1%.
• The New York State Common Retirement Fund increased its stake in ZBH by 24.9% (to ~208k shares), while Bank of New York Mellon reduced its holdings by 2.3%, indicating mixed institutional sentiment.
• Management recently issued a cautious outlook for 2026 at a major healthcare conference, citing internal resets and weak demand in specific international markets like the Middle East.
• The FDA's new Quality Management System Regulation (QMSR) became effective February 2, 2026, harmonizing U.S. device manufacturing standards with international ISO 13485:2016 requirements.
• A joint regulatory reliance pilot program was launched between Malaysia and Thailand on February 1, 2026, aiming to streamline approval timelines for Class B, C, and D medical devices in Southeast Asia.

• ZBH Stock Price 24h change: +0.31%. From 85.71 USD to 86.02 USD.• Yesterday's marginal gain reflects a stabilizing attempt after hitting a new 52-week low earlier in the week, though investor sentiment remains fragile due to recent cautious guidance for 2026.• Technical indicators are currently bearish: the stock is trading near its key support level of 84.59 USD, with the RSI neutral at 31.8 and moving averages (SMA 20, 50, and 200) all trending downward, signaling persistent short-term weakness.• UBS lowered its price target for Zimmer Biomet to $86 from $88, maintaining a "Sell" rating due to concerns over inconsistent growth and international order cancellations.• Hagens Berman announced an investigation into Zimmer Biomet regarding potential misrepresentations of its 2025 revenue targets following a series of disappointing financial disclosures.• Zimmer Biomet announced it will release its Q4 2025 financial results on February 10, 2026, which is expected to provide further clarity on its "internal reset" strategy.• The EU Commission has proposed new amendments to the medical device regulatory framework (MDR/IVDR) to simplify administrative burdens and support innovation within the MedTech sector.• The FDA launched the TEMPO digital health pilot program, aimed at streamlining the review process for software-based medical devices and wearable health technologies.